TLDR
- Novo Nordisk stock climbs 2.83% after CHMP backs FREHEMGO for EU approval plans.
- FREHEMGO targets haemophilia A with weekly, biweekly, or monthly dosing options.
- FRONTIER trials showed low bleeding rates across adult and child patient groups.
- Novo plans first European FREHEMGO launches during the fourth quarter of 2026.
- US regulators are also reviewing denecimig after Novo’s September 2025 filing.
Novo Nordisk (NVO) stock gained 2.83% to $42.89 after European regulators backed FREHEMGO for haemophilia A treatment. The positive recommendation moves the drug closer to commercial approval across European Union markets. Meanwhile, Novo Nordisk plans initial European launches during the fourth quarter of 2026.
Novo Nordisk Gains After FREHEMGO Receives CHMP Backing
Novo Nordisk received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use. The committee recommended marketing authorisation for FREHEMGO, also known as denecimig, for haemophilia A. The recommendation covers adults and children with or without factor VIII inhibitors.
FREHEMGO is a next-generation factor VIIIa mimetic bispecific antibody developed for routine preventive treatment. The medicine aims to reduce bleeding episodes while offering patients several dosing schedules. Novo designed the treatment for weekly, biweekly, or monthly administration using a pre-filled pen.
The regulatory development supported Novo Nordisk stock during Thursday’s trading session. NVO shares climbed toward the $43 level following a strong late-morning advance. The move came as the European recommendation strengthened expectations for another product expansion.
FRONTIER Trials Support FREHEMGO Approval Application
Novo based its European application on data from the broader FRONTIER clinical development programme. FRONTIER 2 evaluated adults and adolescents aged 12 years and older. The trial tested weekly and monthly dosing schedules across haemophilia A patient groups.
Results showed denecimig reduced annualised bleeding rates compared with previous preventive and on-demand treatments. Meanwhile, FRONTIER 3 studied children below 12 years using similar dosing schedules. The paediatric results remained consistent with findings reported among adolescents and adults.
Across phase three studies, mean annualised bleeding rates generally remained below one. A substantial portion of participants also recorded no treated bleeding episodes during the trials. These findings provided supporting evidence for Novo’s European marketing authorisation application.
Novo Nordisk Prepares European FREHEMGO Launch
Novo Nordisk expects to introduce FREHEMGO in selected European countries during the fourth quarter of 2026. The company then plans a broader European Union rollout beginning in early 2027. However, final marketing authorisation still depends on the European Commission’s regulatory decision.
FRONTIER 4 also examined biweekly dosing and longer-term safety across the available treatment schedules. Separately, FRONTIER 5 evaluated patients who switched directly from emicizumab to denecimig preventive treatment. That study identified no new safety signals following the treatment switch.
Novo Nordisk has spent more than four decades developing treatments for people living with haemophilia. The company also submitted denecimig to the US Food and Drug Administration in September 2025. That Biologics License Application places FREHEMGO within Novo’s wider strategy to expand its haemophilia treatment portfolio.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
